Get the Stockscreener App
0.3606
10.52%
-0.0424
Pre-market:
.36
-0.0006
-0.17%
Jupiter Neurosciences Inc stock is traded at $0.3606, with a volume of 156.02K.
It is down -10.52% in the last 24 hours and down -2.20% over the past month.
Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.
See More
Previous Close:
$0.403
Open:
$0.399
24h Volume:
156.02K
Relative Volume:
1.20
Market Cap:
$13.08M
Revenue:
-
Net Income/Loss:
$-8.64M
P/E Ratio:
-1.408
EPS:
-0.2561
Net Cash Flow:
$-5.41M
1W Performance:
-2.09%
1M Performance:
-2.20%
6M Performance:
-73.49%
1Y Performance:
-42.03%
1-Day Range:
$0.3605
$0.4003
1-Week Range:
$0.35
$0.4189
52-Week Range:
$0.3062
$3.33
Jupiter Neurosciences Inc Stock (JUNS) Company Profile
Name
Jupiter Neurosciences Inc
Sector
Industry
Phone
(561) 406-6154
Address
1001 NORTH US HWY 1, JUPITER
Compare JUNS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JUNS
Jupiter Neurosciences Inc
|
0.3606 | 13.08M | 0 | -8.64M | -5.41M | -0.2561 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Jupiter Neurosciences Inc Stock (JUNS) Latest News
Jupiter Neurosciences, Inc. to Present at The Market Movers Investor Summit - TradingView
[EFFECT] JUPITER NEUROSCIENCES, INC. SEC Filing - Stock Titan
JUPITER NEUROSCIENCES INC (JUNS) Fundamental Analysis & Valuation - ChartMill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Jupiter: Rise in AUMs Driven by CCLA Acquisition Completion, Net Inflows - Moomoo
Jupiter Neurosciences to Present at BIO Investment and Growth Summit 2026 - WFXG
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Jupiter Neurosciences (NASDAQ: JUNS) files shelf to sell up to $100M in securities - Stock Titan
Stock List: Research Stocks from Around the World - GuruFocus
Jupiter Neurosciences, Inc. to Present at Centri Capital Conference on April 14 - The Globe and Mail
Nasdaq hosts Jupiter Neurosciences CEO at April 14 investor conference - Stock Titan
Jupiter Neurosciences Investor News: Rosen Law Firm Encourages Jupiter Neurosciences, Inc. Investors to Inquire About Securities Class Action Investigation – JUNS - The Joplin Globe
Growth Review: Will Jupiter Neurosciences Inc benefit from rising consumer demand2026 Update & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Winners Losers: What are analysts price targets for EMP PRAEarnings Risk Summary & Weekly Breakout Watchlists - baoquankhu1.vn
Rosen Law Firm Encourages Jupiter Neurosciences, Inc. Investors to Inquire About Securities Class Action Investigation – JUNS - Caledonian Record
JUNS PE Ratio & Valuation, Is JUNS Overvalued - Intellectia AI
Forecast Cut: What analysts say about Jupiter Neurosciences Inc stockWeekly Profit Report & Safe Capital Growth Plans - baoquankhu1.vn
Swing Trade: Can Avis Budget Group Inc sustain earnings growth2026 Key Lessons & Stepwise Trade Signal Guides - baoquankhu1.vn
Jupiter Neurosciences Appoints Kristopher Fishman and Sanjiv Lal to Nugevia™ Advisory Board - The National Law Review
Investment Review: Will Jupiter Neurosciences Inc benefit from rising consumer demandMarket Movers & Safe Entry Point Identification - baoquankhu1.vn
Jupiter Neurosciences adds advisors for consumer product line By Investing.com - Investing.com Australia
Jupiter Neurosciences Appoints Kristopher Fishman and Sanjiv Lal to Nugevia Advisory Board - Bitget
Jupiter Neurosciences adds advisors for consumer product expansion By Investing.com - Investing.com Canada
Jupiter Neurosciences adds advisors for consumer product expansion - Investing.com
Jupiter Neurosciences adds advisors for consumer product line - Investing.com
Breakout Move: Is Jupiter Neurosciences Inc forming a bullish divergence2026 Key Lessons & Safe Swing Trade Setups - baoquankhu1.vn
JUNS SEC FilingsJUPITER NEUROSCIENCES, INC. 10-K, 10-Q, 8-K Forms - Stock Titan
How does earnings affect Jupiter Neurosciences (JUNS) Stock | Price at $0.40, Up 4.18%Stock Market Community - Newser
JUNS Stock Analysis: Jupiter Neurosciences Inc. Biotech 2.9% Dip Update at $0.37 - UBND thành phố Hải Phòng
Jupiter Neurosciences, Inc. Advances JOTROL™ Resveratrol Platform for Neuroinflammation Treatments and Launches Nugevia Longevity Supplements 69 70 73 108 - Minichart
Jupiter Neurosciences Delays Annual 10-K Filing - TipRanks
Jupiter Neurosciences 2025 10-K: $21.8K Revenue, $0.00 EPS (net loss $8.64M) - TradingView — Track All Markets
Jupiter Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Jupiter Neurosciences (JUNS) flags going concern risk and expands JOTROL, Nugevia strategy - stocktitan.net
[NT 10-K] JUPITER NEUROSCIENCES, INC. SEC Filing - stocktitan.net
Breakout Move: Will Jupiter Neurosciences Inc benefit from geopolitical trends2026 Levels & Daily Momentum Trading Reports - baoquankhu1.vn
North Country Limousine Opens 2026 Wine Tour Reservations for Long Island’s North Fork - weeklyvoice.com
Jupiter Neurosciences to Present at Emerging Growth Conference on April 2 - The Norfolk Daily News
Investors can hear Jupiter Neurosciences outline progress Apr. 2 - Stock Titan
Will The GEO Group Inc outperform during market ralliesPortfolio Value Summary & Weekly Return Optimization Plans - baoquankhu1.vn
Nasdaq Moves: Does Jupiter Neurosciences Inc outperform in volatile marketsQuarterly Investment Review & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Growth Recap: How is Mersana Therapeutics Inc managing supply chain issues2026 Market Outlook & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Market Moves: What analysts say about Jupiter Neurosciences Inc stockWeekly Trade Summary & Reliable Momentum Entry Alerts - baoquankhu1.vn
Centri - TMX Newsfile
Jupiter Neurosciences Inc Stock (JUNS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):